{"title":"银屑病患者接受赛库单抗治疗后出现大疱性丘疹的病例报告。","authors":"Guanghan Wang, Xiaojing Hu, Shixin Han, Meijuan Zhou","doi":"10.1080/09546634.2024.2366535","DOIUrl":null,"url":null,"abstract":"<p><p><b>Aim:</b> Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare.</p><p><p><b>Methods:</b> We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab.</p><p><p><b>Results:</b> Scattered tense vesicles with itching appeared all over the body after the fourth treatment. Bullous pemphigoid was confirmed by pathological examination and direct immunofluorescence. The patient was treated with topical corticosteroids, oral nicotinamide and minocycline hydrochloride. The lesions of bullous pemphigoid improved significantly after 7 days of treatment.</p><p><p><b>Conclusions:</b> Bullous pemphigoid is a rare adverse event following administration of secukinumab.</p>","PeriodicalId":94235,"journal":{"name":"The Journal of dermatological treatment","volume":"35 1","pages":"2366535"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis.\",\"authors\":\"Guanghan Wang, Xiaojing Hu, Shixin Han, Meijuan Zhou\",\"doi\":\"10.1080/09546634.2024.2366535\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Aim:</b> Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare.</p><p><p><b>Methods:</b> We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab.</p><p><p><b>Results:</b> Scattered tense vesicles with itching appeared all over the body after the fourth treatment. Bullous pemphigoid was confirmed by pathological examination and direct immunofluorescence. The patient was treated with topical corticosteroids, oral nicotinamide and minocycline hydrochloride. The lesions of bullous pemphigoid improved significantly after 7 days of treatment.</p><p><p><b>Conclusions:</b> Bullous pemphigoid is a rare adverse event following administration of secukinumab.</p>\",\"PeriodicalId\":94235,\"journal\":{\"name\":\"The Journal of dermatological treatment\",\"volume\":\"35 1\",\"pages\":\"2366535\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of dermatological treatment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/09546634.2024.2366535\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/30 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of dermatological treatment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/09546634.2024.2366535","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/30 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
A case report of bullous pemphigoid following secukinumab therapy for a patient with psoriasis.
Aim: Bullous pemphigoid induced by secukinumab in treatment of psoriasis is rare.
Methods: We report a 49-year-old man with psoriasis who developed bullous pemphigoid during treatment with secukinumab.
Results: Scattered tense vesicles with itching appeared all over the body after the fourth treatment. Bullous pemphigoid was confirmed by pathological examination and direct immunofluorescence. The patient was treated with topical corticosteroids, oral nicotinamide and minocycline hydrochloride. The lesions of bullous pemphigoid improved significantly after 7 days of treatment.
Conclusions: Bullous pemphigoid is a rare adverse event following administration of secukinumab.